What is the GLOW Peptide Blend? GHK-Cu, BPC-157, and TB-500 Explained
Compound Spotlight
GLOW is a blend of three peptides in a single vial: GHK-Cu, BPC-157, and TB-500. Each one has its own research history, its own studied mechanism, and its own body of literature behind it. This article walks through each compound individually, why they are often studied together, and what the actual research says about each one.
GHK-Cu
GHK-Cu (glycyl-L-histidyl-L-lysine, bound to copper) is a naturally occurring tripeptide first isolated from human plasma in the 1970s by researcher Loren Pickart. It was noticed originally because plasma from younger donors showed higher levels of it compared to plasma from older donors, which is part of why it has been studied so extensively in the context of aging and tissue repair.
What it is studied for
- Collagen and elastin production in skin research
- Wound healing and tissue remodeling models
- Antioxidant and anti-inflammatory activity
- Hair follicle activity in dermatological research
How it is thought to work
GHK-Cu is studied for its role as a copper carrier. Copper is a cofactor for several enzymes involved in tissue remodeling, including lysyl oxidase, which helps cross-link collagen and elastin. Research has also looked at GHK-Cu’s effect on gene expression, with some studies suggesting it can shift the expression of genes associated with tissue repair and away from those associated with inflammation.
BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic peptide made up of 15 amino acids, based on a sequence found in a protective protein present in human gastric juice. It was first researched in the 1990s at the University of Zagreb, primarily in the context of gastrointestinal healing, before its research scope expanded into soft tissue.
What it is studied for
- Gastrointestinal lining protection and repair
- Tendon, ligament, and muscle injury models
- Angiogenesis (new blood vessel formation) in damaged tissue
- Anti-inflammatory activity in animal models
How it is thought to work
Much of the research on BPC-157 centers on its interaction with the nitric oxide system, which plays a role in blood vessel formation and tissue repair. Animal studies have also looked at its effect on growth hormone receptor expression in tendon fibroblasts, which is one proposed mechanism for its studied role in tendon-to-bone healing. Human clinical trial data remains limited, and most of the existing research is in animal models.
TB-500
TB-500 is a synthetic version of a fragment of Thymosin Beta-4, a naturally occurring protein found in nearly all human and animal cells. Thymosin Beta-4 itself has been studied since the 1960s, initially in the context of wound healing and cell growth. TB-500 refers specifically to the synthetic, shorter-chain version used in research settings.
What it is studied for
- Cell migration during tissue repair
- Wound healing models
- Flexibility and range of motion research in soft tissue
- Reduction of inflammatory markers in animal studies
How it is thought to work
TB-500’s studied mechanism centers on actin regulation. Actin is a protein that forms part of the cell’s internal structure and is directly involved in how cells move. By binding to actin, TB-500 is thought to help regulate cell migration to and from injury sites, which is the basis for most of its studied applications in tissue regeneration research.
Why these three are often studied together
Each of these three peptides is studied along a different mechanism, but they converge on a similar research area: tissue repair and recovery. GHK-Cu is studied for its role in collagen synthesis and skin-level repair. BPC-157 is studied for its role in blood vessel formation and gut-related healing. TB-500 is studied for cell migration to injury sites. Because the three mechanisms are studied as complementary rather than overlapping, researchers frequently combine them in a single formulation rather than running each one separately.
Our GLOW Blend
Our GLOW Blend combines all three in a single vial at a 50mg / 10mg / 10mg ratio (GHK-Cu / BPC-157 / TB-500), 70mg total per vial. Every lot we sell is sent to an independent, third-party lab before it is listed, and the resulting Certificate of Analysis is published for that exact lot. The current batch (lot 24-171) tested at 99.0% purity.
Frequently asked questions
Is GLOW the same as buying each peptide separately?
The active compounds are the same. GLOW simply combines all three into one vial at a fixed ratio, rather than requiring three separate purchases and three separate reconstitutions.
How do I know what is actually in the vial?
Every lot we sell has a published Certificate of Analysis from an independent, third-party lab, confirming both identity and purity. You can look up any lot number directly on our site.
Where does the research on these peptides come from?
Each of these three peptides has a body of published research behind it, ranging from foundational discovery-era studies (GHK-Cu in the 1970s, Thymosin Beta-4 in the 1960s, BPC-157 in the 1990s) to more recent animal-model research. Most existing data is preclinical (animal or in-vitro), and human clinical trial data remains limited for all three.
View the GLOW Blend product listing →
Look up lot 24-171 Certificate of Analysis →
For laboratory and research use only. Not for human consumption. This article is for informational purposes and summarizes existing published research; it is not medical advice.
